Clinical trials: HCV, open to volunteers
Hepatitis C Virus (HCV)
Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data
The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.
- Trial name
- NCT07419347
- Where
- 2 sites in Canada
- Volunteers
- 2,000 people
- Sponsor
- AbbVie
Cirrhosis, Cirrhosis, Liver
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B
- Trial name
- LCN RESCU (NCT05832229)
- Testing
- Rosuvastatin
- Where
- 13 sites in United States
- Volunteers
- 260 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV)
Combating Related Epidemics in HCV
This is a two-arm cluster randomized control trial to evaluate the effectiveness of a single-visit point-of-care (POC) test and treat bundle (intervention arm) compared to the current standard-of-care (SOC, control arm).
- Conditions
- HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV), HEPATITIS C (HCV)
- Trial name
- CREST (NCT07560046)
- Testing
- Cepheid GeneXpert HCV Test, Abbott Determine HIV - 1/2 Ag/Ab, Abbott Determine HbsAg 2
- Volunteers
- 1,280 people
- Sponsor
- Duke University
HIV Pre-exposure Prophylaxis, HEPATITIS C (HCV)
Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Pilot Testing: Aim3)
Evaluate the feasibility, acceptability, and usability of the intervention (primary outcomes) and coping skills and resilience (secondary outcomes) of the telehealth intervention over two months (8 weekly sessions) in a…
- Conditions
- HIV Pre-exposure Prophylaxis, HEPATITIS C (HCV), Opioid Use Disorder
- Trial name
- NCT06799702
- Testing
- Telehealth Behavioral Intervention for promoting HIV and HCV care and MOUD among Persons who inject drugs (PWID)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Georgia
Chronic Hepatitis C Infection
HEPATITIS C SCREENING in ADULTS with RISK FACTORS in FIVE CITIES of COLOMBIA'S CARIBBEAN COAST (FIVE-CC)
Hepatitis C virus (HCV) infection is a significant cause of chronic hepatitis, cirrhosis, and liver cancer (1). The risk of developing cirrhosis in people with chronic HCV infection ranges between 15% and 30% over a period of 20…
- Trial name
- FIVE-CC (NCT06899542)
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Diana Rocio Chavez Bejarano
Hepatitis C Virus Infection
Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy
Hepatitis C is a common and potentially serious disease. However, there are treatments that can cure it. That's why it's so important to detect the hepatitis C virus (HCV) and treat those affected.
- Trial name
- ACCESS+ (NCT07098481)
- Testing
- ACCESS+ strategy Epclusa 400/100 Oral Tablet, ACCESS+ Strategy Vosevi 400/100/100 Oral Tablet, Standard Strategy Vosevi 400/100/100 Oral Tablet
- Volunteers
- 576 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C
The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry
Clinical interventions to reduce the risk of vertical transmission of hepatitis C virus (HCV) infection from mother to infant are highly limited.
- Trial name
- TiP-HepC (NCT05368974)
- Testing
- Direct Acting Antivirals
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Task Force for Global Health
Hepatitis C
Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil)
Up to 650,000 people in Brazil are living with chronic hepatitis c virus (HCV) infection. Hepatitis C is a silent disease, and up to 20% of cases can progress to liver cirrhosis and its complications.
- Trial name
- HCVPCL05/20 (NCT06306300)
- Testing
- Specialist - Epclusa 400Mg-100Mg Tablet, Non- specialist - Epclusa 400Mg-100Mg Tablet, HCV Self-Testing kit (Ora-Quick HCV ST or Wond-Foo HCV ST)
- Where
- 2 sites in Brazil
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
Hepatitis C
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir
This study aims to evaluate the efficacy, safety and feasibility of four weeks of sofosbuvir plus glecaprevir-pibrentasvir, followed by immediate retreatment of virological relapse with glecepravir-pibrentasvir for 12 weeks, in…
- Trial name
- STRIVE-4 (NCT03855917)
- Testing
- Sofosbuvir 400mg [Sovaldi], Glecaprevir/pibrentasvir (300mg/120mg)
- Where
- 3 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Kirby Institute
HBV, HCV
Non-interventional Study to Assess the Number of People With Untreated/Unknown HBV + HDV and HCV in South-East Austria
The HEAL-S study is a non-interventional study with retrospective data analysis. It consists of two parts. First a retrospective analysis based on nucleic acid testing (NAT) results will be performed.
- Conditions
- HBV, HCV, HDV, Coinfection
- Trial name
- HEAL-S (NCT06834178)
- Where
- Austria
- Volunteers
- 100 people
- Sponsor
- Vanessa Stadlbauer-Koellner, MD
HCV Infection
Drug-Drug Intercations and Direct Acting Antiviral Agents Against HCV
Background: Currently used direct-acting antivirals (DAA) share pharmacokinetic pathways with many comedications commonly used in patients with chronic hepatitis C virus (HCV) infection, therefore drug-drug interactions (DDI)…
- Trial name
- NCT06928259
- Where
- 4 sites in Spain
- Volunteers
- 728 people
- Sponsor
- University of Seville
Hepatitis C
Treatment as Prevention for Hepatitis C in Iceland
The main aim of this study is to test in the Icelandic population the hypothesis that a nationwide treatment program which offers effective treatment to all known cases of Hepatitis C with the aim of halting HCV (Hepatitis C…
- Trial name
- TraPHepC (NCT02647879)
- Where
- Iceland
- Volunteers
- 1,000 people
- Sponsor
- Landspitali University Hospital
Hepatocellular Carcinoma (HCC)
Role of Long Noncoding RNA LINC01134 in Metastasis of Hepatitis C Virus-related Hepatocellular Carcinoma
LINC01134, a novel lncRNA, has received increasing attention in cancer research, particularly in hepatocellular carcinoma (HCC).
- Trial name
- NCT07130474
- Volunteers
- 50 people
- Sponsor
- Sohag University
Hepatitis C Virus Infection
Characterization of Immune Genotypes and Antibody Profiles to Foster the discoVERY of diagnosticbioMARKERS of Liver Cancer Development
Hepatitis C virus (HCV), which infects more than 185 million people, is a major risk factor. Direct-acting antiviral (DAA) therapy has significantly improved the eradication of the virus, but has not completely eliminated the…
- Trial name
- VERYMARKERS (NCT06718530)
- Where
- 4 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Hepatitis C
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
The investigators will conduct a randomized controlled clinical trial study in an urban emergency department in Baltimore to determine the impact of an educational app which is based on Leventhal's Common-Sense Model of Illness…
- Trial name
- NCT04162938
- Testing
- Patient-Centered Electronic App
- Where
- United States
- Volunteers
- 308 people
- Sponsor
- Johns Hopkins University
Hepatitis C
The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset
The goal of this observational study is to learn if offering a point-of-care screening test for exposure to the Hepatitis C virus, before providing a diagnostic test for Hepatitis C infection can increase testing, diagnosis and…
- Trial name
- NCT05713136
- Testing
- Diagnostic Test: Point-of-Care Testing
- Where
- 13 sites in Australia
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Heart Failure
Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients
This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).
- Trial name
- TROJAN-C (NCT03383419)
- Testing
- Epclusa
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Baylor Research Institute
Hepatitis C
A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial)
The purpose of this study is to investigate the safety and antibody (germ fighters) response of the experimental (investigational) vaccine against HCV when injected into the arm of healthy adults.
- Trial name
- NCT07237282
- Testing
- AVIHepC1, Normal Saline
- Where
- 3 sites in Canada
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Liver Diseases, Humans
Liver Disease and Other Systemic Diseases
Examine the association of chronic liver diseases (including hepatitis B, hepatitis C, alcoholic liver disease, fatty liver, liver cirrhosis, and hepatocellular carcinoma) with other systemic diseases by retrospectively analyzing…
- Conditions
- Liver Diseases, Humans, Progression, Carcinogenesis
- Trial name
- NCT04525833
- Where
- Taiwan
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
HIV, Hepatitis C Virus (HCV)
Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons
This study is focused on improving the implementation of Prison Needle Exchange Programs (PNEPs) in Canadian federal prisons, with the goal of increasing the uptake of these programs among people who inject drugs in prison.
- Trial name
- NCT07122219
- Testing
- NIATx
- Where
- 9 sites in Canada
- Volunteers
- 548 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre